{"id":19294,"date":"2018-05-18T10:46:51","date_gmt":"2018-05-18T08:46:51","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=19294"},"modified":"2025-01-29T13:34:30","modified_gmt":"2025-01-29T12:34:30","slug":"may-18-2018-dermapharm-holding-se-publishes-q1-2018-report","status":"publish","type":"post","link":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/","title":{"rendered":"<span id=\"2018\" class=\"Postdate\">May 18, 2018<\/span> | Dermapharm Holding SE publishes Q1 2018 report"},"content":{"rendered":"<style>\n.zur\u00fcckbutton:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #00225f;\n    margin-right: 7px;\n}\n.zur\u00fcckbutton:hover:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #d85710;\n    margin-right: 7px;\n}\n<\/style>\n<h1 style=\"text-align: justify;\">Corporate news<\/h1>\n<p> <a class=\"zur\u00fcckbutton\" href=\"https:\/\/cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<h1>Dermapharm Holding SE publishes Q1 2018 report <\/h1>\n<ul>\n<li>Revenues increased by 16.4% to EUR 137.5 million <\/li>\n<li>Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% <\/li>\n<li>International presence continued to expand with sales subsidiary in Italy <\/li>\n<li>Integration of Strathmann and Trommsdorff on schedule<\/li>\n<\/ul>\n<p><strong>Gr\u00fcnwald, May 18, 2018<\/strong> \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading producer of patent-free branded pharmaceuticals for select therapeutic areas in Germany with a growing international presence, published its report for the first three months of 2018 today, having increased its revenues by 16.4% to EUR 137.5 million (prior-year quarter: EUR 118.1 million). Earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off costs of EUR 0.7 million in connection with IPO preparations, were EUR 36.2 million, 25.3% higher than in the same quarter last year (EUR 28.9 million). The adjusted EBITDA margin was 26.3%, 1.8 percentage points above the margin of the previous year. Unadjusted EBITDA amounted to EUR 35.5 million while the unadjusted EBITDA margin was 25.8%. <\/p>\n<p>Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE, comments: \u201cThe first quarter of 2018 was characterized by our three-pillar strategy of in-house product development, internationalization and successful acquisitions. Together with the integration of Strathmann and Trommsdorff, we were able to expand our portfolio to include over-the-counter top sellers such as Keltican\u00ae forte, Tromcardin\u00ae complex and Ebenol\u00ae and at the same time acquire very promising prescription products for our core therapeutic areas. This has strengthened the share of branded therapeutics in our overall portfolio and reduced our dependence on direct health insurance discount contracts. Establishing mibe pharma Italia Srl in Bolzano in the first quarter was another important step in expanding our international presence and opening up the promising Italian market for our products.\u201d <\/p>\n<p>Revenues in the segment \u201cBranded Pharmaceuticals and Other Healthcare Products\u201d increased by 43.0% to EUR 79.5 million (prior-year quarter: EUR 55.6 million). The adjustment for one-off costs in connection with the IPO preparation relates entirely to this segment. Therefore, adjusted EBITDA in this segment increased by 26.4% to EUR 34.5 million, the unadjusted EBITDA increased by 23.8% to EUR 33.8 million (prior-year quarter: EUR 27.3 million). The increase is due in large part to positive gross profit development along with reductions in expenditures for discounts from direct contracts with health insurance companies and in materials costs. The acquisitions of the Strathmann Group and the Trommsdorff Group were also included in the consolidation of this segment for the first time. As a result of this first-time consolidation, the segment\u2019s EBITDA margin of 43.3% (adjusted) resp. 42.4% (unadjusted) was down from the prior-year quarter (49.1%). The integration of the two companies is proceeding according to plan and the Management Board expects further synergy effects in the Group for the future, which will have a positive impact on the individual margins. <\/p>\n<p>In the \u201cParallel Import Business\u201d segment, revenues fell by 7.2% to EUR 58.0 million in the reporting period (prior-year quarter: EUR 62.5 million). This decline was mainly due to the concentration on highmargin yet small-volume preparations. The German parallel import market is dominated by three very large-volume products, which achieve only very low margins due to the current market concentration on a few wholesalers in a few countries. Dermapharm therefore only made small purchases of these preparations in the first quarter of 2018, but expects improved margins already in the course of the current second quarter of 2018 due to new wholesalers in more European countries, setting the stage an increasing revenue dynamic in the Parallel Import Business in the coming quarters. EBITDA for the Parallel Import Business increased significantly in the first quarter by 68.8% to EUR 2.7 million (prioryear quarter: EUR 1.6 million). Dermapharm achieved this by optimizing its product portfolio, increasing the gross profit margin through demand-oriented purchasing and constant cost optimization in all areas. The EBITDA margin in Parallel Imports increased accordingly from 2.6% in the prior-year quarter to 4.7%. <\/p>\n<p>With the positive business development in the first quarter of 2018 and assuming unchanged conditions, the Management Board confirms its full-year forecast of revenue growth of 20 to 25% and an improvement in EBITDA of 22 to 27% over fiscal year 2017. <\/p>\n<p>The complete quarterly report is available as of today online at ir.dermapharm.com. <\/p>\n<p>Key financial figures for Q1 2018 year-on-year <\/p>\n<table class=\"tableizer-table\">\n<thead>\n<tr class=\"tableizer-firstrow\">\n<th>in EUR millions <\/th>\n<th>Q1\/2018 <\/th>\n<th>Q1\/2017 <\/th>\n<th>Change <\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Group sales <\/td>\n<td>137.5 <\/td>\n<td>118.1 <\/td>\n<td>+ 16.4% <\/td>\n<\/tr>\n<tr>\n<td>Branded Pharmaceuticals and Other Health Products <\/td>\n<td>79.5 <\/td>\n<td>55.6 <\/td>\n<td>+ 43.0% <\/td>\n<\/tr>\n<tr>\n<td>Parallel Import Business <\/td>\n<td>58.0 <\/td>\n<td>62.5 <\/td>\n<td>&#8211; 7.2% <\/td>\n<\/tr>\n<tr>\n<td>Reconciliation \/ Group holding <\/td>\n<td>&#8211; <\/td>\n<td>&#8211; <\/td>\n<td>&#8211; <\/td>\n<\/tr>\n<tr>\n<td>Adjusted\u00b9 Group EBITDA <\/td>\n<td>36.2 <\/td>\n<td>28.9 <\/td>\n<td>+ 25.3% <\/td>\n<\/tr>\n<tr>\n<td>Adjusted\u00b9 EBITDA margin (in %) <\/td>\n<td>26.3 <\/td>\n<td>24.5 <\/td>\n<td>+ 1.8pp <\/td>\n<\/tr>\n<tr>\n<td>Group EBITDA <\/td>\n<td>35.5 <\/td>\n<td>28.9 <\/td>\n<td>+ 22.8% <\/td>\n<\/tr>\n<tr>\n<td>Branded Pharmaceuticals and Other Health Products <\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>adjusted\u00b9 <\/td>\n<td>34.5 <\/td>\n<td>27.3 <\/td>\n<td>+ 26.4% <\/td>\n<\/tr>\n<tr>\n<td>unadjusted <\/td>\n<td>33.8 <\/td>\n<td>27.3 <\/td>\n<td>+ 23.8% <\/td>\n<\/tr>\n<tr>\n<td>Parallel Import Business <\/td>\n<td>2.7 <\/td>\n<td>1.6 <\/td>\n<td>+ 68.8% <\/td>\n<\/tr>\n<tr>\n<td>Reconciliation \/ Group holding <\/td>\n<td>-1.0 <\/td>\n<td>&#8211; <\/td>\n<td>&#8211; <\/td>\n<\/tr>\n<tr>\n<td>EBITDA margin (in %) <\/td>\n<td>25.8 <\/td>\n<td>24.5 <\/td>\n<td>+ 1.3pp <\/td>\n<\/tr>\n<tr>\n<td>Branded Pharmaceuticals and  Other Health Products <\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>adjusted\u00b9 <\/td>\n<td>43.3 <\/td>\n<td>49.1 <\/td>\n<td>&#8211; 5,8pp <\/td>\n<\/tr>\n<tr>\n<td>unadjusted <\/td>\n<td>42.4 <\/td>\n<td>49.1 <\/td>\n<td>&#8211; 6.7pp <\/td>\n<\/tr>\n<tr>\n<td>Parallel Import Business <\/td>\n<td>4.7 <\/td>\n<td>2.6 <\/td>\n<td>+ 2.1pp <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\u00b9 2018 adjusted for one-off costs in connection with the preparation of the stock exchange listing in the amount of EUR 0.7 million<\/p>\n<p>Company profile:<br \/>\nDermapharm \u2013 Pharmaceutical Excellence &#8220;Made in Germany&#8221;<br \/>\nDermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Gr\u00fcnwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company\u2019s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 200 active pharmaceutical ingredients, which are reflected in a broad assortment of products. This assortment makes the company unique. In addition to Germany, the company\u2019s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm\u2019s business model also includes a parallel import business, which operates under the \u201caxicorp\u201d brand. Based on revenues, Dermapharm was among the top four parallel import companies in Germany in 2017. <\/p>\n<p>With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on three strategic growth drivers: in-house development of new products, increase of its international footprint and further acquisitions. These include the acquisition of the pharmaceuticals manufacturer and distributor Trommsdorff in January 2018, whose portfolio includes the well-known brands Keltican\u00ae forte and Tromcardin\u00ae complex. <\/p>\n<p>Contact<br \/>\ncometis AG<br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nE-mail: ir@dermapharm.de<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Post as PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/e_180518_CN_Dermapharm_Q1_2018.pdf\" target=\"_blank\" rel=\"noopener\">Post as PDF<\/a><\/div>\n<style>\n.leseprobe-archiv {\n    color: #00225f !important;\n    border-color: #00225f;\n    position: relative;\n    padding: 0.3em 1em;\n    border: 1px solid;\n    -webkit-border-radius: 3px;\n    -moz-border-radius: 3px;\n    border-radius: 3px;\n   -webkit-transition: all 0.2s;\n    -moz-transition: all 0.2s;\n    transition: all 0.2s;\n    padding:10px;\n    width: 19%;\n    text-align: center;\n    margin-right: 10px;\n    float:left;\n}\n.leseprobe-archiv:hover {\n    background-color: #eee;\n    border-color: #ffffff;\n    cursor: pointer;\n}\n<\/style>\n","protected":false},"excerpt":{"rendered":"<p>Corporate news to the archive Dermapharm Holding SE publishes Q1 2018 report Revenues increased by 16.4% to EUR 137.5 million Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% International presence continued to expand with sales subsidiary in Italy Integration of Strathmann and Trommsdorff on schedule Gr\u00fcnwald, May 18, 2018 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":98872,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[215,90],"tags":[225],"class_list":["post-19294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-2018-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.2 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report\" \/>\n<meta property=\"og:description\" content=\"Corporate news to the archive Dermapharm Holding SE publishes Q1 2018 report Revenues increased by 16.4% to EUR 137.5 million Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% International presence continued to expand with sales subsidiary in Italy Integration of Strathmann and Trommsdorff on schedule Gr\u00fcnwald, May 18, 2018 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-18T08:46:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T12:34:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1\"},\"headline\":\"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report\",\"datePublished\":\"2018-05-18T08:46:51+00:00\",\"dateModified\":\"2025-01-29T12:34:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/\"},\"wordCount\":1028,\"publisher\":{\"@id\":\"https:\/\/www.cometis.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"keywords\":[\"2018\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/\",\"url\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/\",\"name\":\"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.cometis.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"datePublished\":\"2018-05-18T08:46:51+00:00\",\"dateModified\":\"2025-01-29T12:34:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage\",\"url\":\"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"width\":172,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cometis.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.cometis.de\/en\/category\/news-en\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cometis.de\/en\/#website\",\"url\":\"https:\/\/www.cometis.de\/en\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/www.cometis.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cometis.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cometis.de\/en\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/www.cometis.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/cometis-ag\/\",\"https:\/\/www.youtube.com\/user\/cometisAG\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cometis.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/","og_locale":"en_US","og_type":"article","og_title":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report","og_description":"Corporate news to the archive Dermapharm Holding SE publishes Q1 2018 report Revenues increased by 16.4% to EUR 137.5 million Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% International presence continued to expand with sales subsidiary in Italy Integration of Strathmann and Trommsdorff on schedule Gr\u00fcnwald, May 18, 2018 [&hellip;]","og_url":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/","og_site_name":"cometis AG","article_published_time":"2018-05-18T08:46:51+00:00","article_modified_time":"2025-01-29T12:34:30+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#article","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1"},"headline":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report","datePublished":"2018-05-18T08:46:51+00:00","dateModified":"2025-01-29T12:34:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/"},"wordCount":1028,"publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"image":{"@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2018"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/","url":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/","name":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage"},"image":{"@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2018-05-18T08:46:51+00:00","dateModified":"2025-01-29T12:34:30+00:00","breadcrumb":{"@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#primaryimage","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","width":172,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cometis.de\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.cometis.de\/en\/category\/news-en\/"},{"@type":"ListItem","position":3,"name":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report"}]},{"@type":"WebSite","@id":"https:\/\/www.cometis.de\/en\/#website","url":"https:\/\/www.cometis.de\/en\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cometis.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cometis.de\/en\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/www.cometis.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cometis-ag\/","https:\/\/www.youtube.com\/user\/cometisAG"]},{"@type":"Person","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/19294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=19294"}],"version-history":[{"count":0,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/19294\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media\/98872"}],"wp:attachment":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=19294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=19294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=19294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}